There are 2867 resources available
53MO - Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116)
Presenter: Arndt Vogel
Session: Mini Oral session: GI, upper digestive
Resources:
Abstract
Slides
Webcast
LBA40 - Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma
Presenter: Celeste Lebbe
Session: Proffered Paper session 1: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
Challenges in the clinical application of Molecular Tumour Boards
Presenter: Alice Indini
Session: Elements to build a Molecular Tumour Board
Resources:
Slides
Webcast
733MO - γδT cells are effectors of immune checkpoint blockade in mismatch repair-deficient colon cancers with antigen presentation defects
Presenter: Joris Van De Haar
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1315O - Key learnings from building: A precision cancer medicine implementation initiative for Norway
Presenter: Kjetil Tasken
Session: Proffered Paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
212MO - AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)
Presenter: Sara Tolaney
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
785O - PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)
Presenter: Adi Diab
Session: Proffered Paper session 1: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
620O - CART-ddBCMA for multiple myeloma: Interim results from phase I study
Presenter: Matthew Frigault
Session: Proffered Paper session: Haematological malignancies
Resources:
Abstract
Slides
Webcast
54MO - Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial
Presenter: Angela Lamarca
Session: Mini Oral session: GI, upper digestive
Resources:
Abstract
Slides
Webcast
734MO - Deep sequencing of the T-cell receptor reveals common and reproducible CD8 T-cell receptor signatures of response to checkpoint immunotherapy
Presenter: Benjamin Fairfax
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast